New Stock Assault 2.0 Product
A brand new Stock Assault 2.0 product has been announced: Stock Assault 2.0 SideKick Edition!
This revolutionary product will give anyone an even greater edge in the stock market. The classic Stock Assault 2.0 delivers stock picks from an unmodifiable AI engine. However, many people expressed interest in being able to train and set up their own AI engine.
The wait is over, Stock Assault 2.0 SideKick Edition is here today!
Learn more about Stock Assault 2.0 SideKick Edition:
* Use in addition to or as a “Sidekick” to Stock Assault 2.0.
* Run any stock or market through Stock Assault 2.0 SideKick Edition and get exact entry and exit points.
* Find out the best possible exit for your current positions.
* Analyze a stock before investing and get the best possible entry.
* Analyze portfolios and predict near-term and long-term ROI.
* Not sure whether to keep holding a position? Stock Assault 2.0 SideKick Edition will predict future movements with jaw-dropping accuracy.
* Never before was anyone able to own an AI engine like this before, we finally made it possible. We prove that knowing future stock movements is possible.
* Full help files included. Very easy to use, just plug in parameters in the step by step wizards and let the AI engine crunch away.
* One time fee only. Free automatic upgrades. No data feed necessary.
==> Learn more about Stock Assault 2.0 SideKick Edition
I think I will stick to picking my own stocks. I’m looking at buying stock in the BioMed industry through a company called Mentor Capital (MNTR.PK), who has acquired a 20% claim in Quantum Immunologics (QI), a privately held company with FDA approved clinical trials for a new breast cancer treatment. According to Breast Cancer Investing, the treatment sensitizes denritic cells in order to expose proteins found only on cancer infected cells allowing the immune system to fight only infected cells. The treatment is safer and has milder side effects then other forms of treatment. As of now, the treatment is most effective on breast cancer, but they believe future research will allow them to extend the treatment to other forms of cancer. The 20% acquisition increases the assets of Mentor Capital by $3.74/share, which may increase as their 20% claim increases with further funding being funneled back into QI. Marketing of this new treatment could send the value of the stock sky high making this an under the radar opportunity for those who get in at the current price of $2.65/share.